Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 3 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Recs

0
Player Avatar chang07 (47.47) Submitted: 4/27/2011 9:34:54 AM : Outperform Start Price: $53.90 VRTX Score: +22.37

Hopefully, the FDA will approve their Hep C drug.

Report this Post Reply

Featured Broker Partners


Advertisement